Browsing by Author "Boachie, C"
Now showing 1 - 13 of 13
- Results Per Page
- Sort Options
Item Clinical and economic evaluation of laparoscopic surgery compared with medical management for gastro-oesophageal reflux disease : 5-year follow-up of multicentre randomised trial (the REFLUX trial)(2013-06) Grant, A M; Boachie, C; Cotton, S C; Faria, R; Bojke, L; Epstein, D M; Ramsay, C R; Corbacho, B; Sculpher, M; Krukowski, Z H; Heading, R C; Campbell, M K; University of Aberdeen.Applied Medicine; University of Aberdeen.Other Applied Health Sciences; University of Aberdeen.Institute of Applied Health SciencesItem The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer : systematic reviews registry database analyses and economic evaluation(2011-08) Robertson, C; Arcot Ragupathy, S K; Boachie, C; Dixon, J M; Fraser, C; Hernández, R; Heys, S; Jack, W; Kerr, G R; Lawrence, G; MacLennan, G; Maxwell, A; McGregor, J; Mowatt, G; Pinder, S; Ternent, L; Thomas, R E; Vale, L; Wilson, R; Zhu, S; Gilbert, F J; University of Aberdeen.Other Applied Health Sciences; University of Aberdeen.Applied Medicine; University of Aberdeen.Institute of Applied Health SciencesItem Conservative treatment for urinary incontinence in Men After Prostate Surgery (MAPS) : two parallel randomised controlled trials(2011-06) Glazener, C; Boachie, C; Buckley, B; Cochran, C; Dorey, G; Grant, A; Hagen, S; Kilonzo, M; McDonald, A; McPherson, G; Moore, K; N'Dow, J; Ramsay, C; Vale, L; University of Aberdeen.Other Applied Health Sciences; University of Aberdeen.Aberdeen Centre for Evaluation; University of Aberdeen.Applied Medicine; University of Aberdeen.Health Economics Research Unit; University of Aberdeen.Academic Urology Unit; University of Aberdeen.Institute of Applied Health SciencesItem Conservative treatment for urinary incontinence in Men After Prostate Surgery (MAPS) : two parallel randomised controlled trials(2011-06) Glazener, C M A; Boachie, C; Buckley, B; Cochran, C; Dorey, G; Grant, A; Hagen, S; Kilonzo, M; McDonald, A; McPherson, G; Moore, K; N'Dow, J; Norrie, J D T; Ramsay, C; Vale, L; University of Aberdeen.Other Applied Health Sciences; University of Aberdeen.Aberdeen Centre for Evaluation; University of Aberdeen.Applied Medicine; University of Aberdeen.Health Economics Research Unit; University of Aberdeen.Academic Urology Unit; University of Aberdeen.Institute of Applied Health SciencesItem The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy : a systematic review and economic evaluation(2013-05) Mowatt, G; Scotland, G; Boachie, C; Cruickshank, M; Ford, J A; Fraser, C; Kurban, L; Lam, T B; Padhani, A R; Royle, J; Scheenen, T W; Tassie, E; University of Aberdeen.Other Applied Health Sciences; University of Aberdeen.Institute of Applied Health Sciences; University of Aberdeen.Medical Education; University of Aberdeen.Medicine, Medical Sciences & Nutrition; University of Aberdeen.Health Economics Research UnitItem Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia : a systematic review and economic evaluation(2012-03) Sharma, P; Boyers, D; Boachie, C; Stewart, F; Miedzybrodzka, Z; Simpson, W; Kilonzo, M; McNamee, P; Mowatt, G; University of Aberdeen.Other Applied Health Sciences; University of Aberdeen.Applied Medicine; University of Aberdeen.Grampian Data Safe Haven (DaSH); University of Aberdeen.Medical Sciences; University of Aberdeen.Institute of Applied Health SciencesItem Minimal access surgery compared with medical management for gastro-oesophageal reflux disease : five year follow-up of a randomised controlled trial (REFLUX)(2013-04-18) Grant, A M; Cotton, S C; Boachie, C; Ramsay, C R; Krukowski, Z H; Heading, R C; Campbell, M K; REFLUX Trial Group; University of Aberdeen.Other Applied Health Sciences; University of Aberdeen.Applied Medicine; University of Aberdeen.Institute of Applied Health SciencesItem A randomised controlled trial evaluating the use of polyglactin (Vicryl) mesh, polydioxanone (PDS) or polyglactin (Vicryl) sutures for pelvic organ prolapse surgery : outcomes at 2 years(2011) Madhuvrata, P; Glazener, C; Boachie, C; Allahdin, S; Bain, C; University of Aberdeen.Medicine, Medical Sciences & Nutrition; University of Aberdeen.Other Applied Health SciencesItem Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura : a single technology appraisal(Gray, 2009) Mowatt, Graham; Boachie, C; Crowther, M; Fraser, Cynthia Mary; Hernández, Rodolfo Andrés; Jia, X; Ternent, LauraThis paper presents a summary of the evidence review group (ERG) report into the clinical and cost-effectiveness of romiplostim for the treatment of adults with chronic immune or idiopathic thrombocytopenic purpura (ITP) based upon a review of the manufacturer’s submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The submission’s evidence came from two relatively high-quality randomised controlled trials (RCTs). The ERG found no evidence that any important data were missed or that data extraction was inaccurate. In both RCTs more patients in the romiplostim than in the placebo group achieved a durable platelet response [non-splenectomised patients: romiplostim 25/41 (61%), placebo 1/21 (5%), odds ratio (OR) 24.45, 95% confidence interval (CI) 3.34 to 179.18; splenectomised patients: romiplostim 16/42 (38%), placebo 0/21 (0%), OR 8.5 (95% CI 1.15 to 372)] and an overall platelet response [non splenectomised patients: romiplostim 36/41 (88%), placebo 3/21 (14%), OR 34.74, 95% CI 7.77 to 155.38; splenectomised patients: romiplostim 33/42 (79%), placebo 0/21 (0%), OR 16.6 (95% CI 2.37 to 706]. The difference in mean period with a platelet response was 13.9 weeks (95% CI 10.5 to 17.4) in favour of romiplostim in the RCT of non-splectomised patients and 12.1 weeks (95% CI 8.7 to 15.6) in favour of romiplostim in the RCT of splectomised patients. The manufacturer’s economic model evaluated the cost-effectiveness of romiplostim compared with standard care. The ERG had concerns about the way the decision problem was addressed in the economic model and about the non-adjustment of findings for confounding factors. In non-splenectomised patients, using romiplostim as a first option treatment, the base-case incremental costeffectiveness ratio (ICER) was £14,840 per quality adjusted life-year (QALY). In splenectomised patients the ICER was £14,655 per QALY. Additional sensitivity analyses performed by the ERG identified two issues of importance: whether individuals entered the model on watch and rescue or on active therapy in the comparator arm (ICER £21,674 per QALY for non-splenectomised patients, £29,771 per QALY for splenectomised patients); whether it was assumed that any unused medicine would be wasted. Combining all of the separate sensitivity analyses, and assuming that watch and rescue was not the first-line treatment, increased the ICERs further (non-splenectomised £37,290 per QALY; splenectomised £131,017 per QALY). In conclusion, the manufacturer’s submission and additional work conducted by the ERG suggest that romiplostim has short-term efficacy for the treatment of ITP, but there is no robust evidence on long-term effectiveness or cost-effectiveness of romiplostim compared with relevant comparators.Item Systematic review of the clinical and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer.(2010-01) Mowatt, G; Zhu, S; Kilonzo, M; Boachie, C; Fraser, C; Griffiths, T R L; N'Dow, J; Nabi, G; Cook, J; Vale, L; University of Aberdeen.Other Applied Health Sciences; University of Aberdeen.Health Economics Research Unit; University of Aberdeen.Aberdeen Centre for Evaluation; University of Aberdeen.Institute of Applied Health Sciences; University of Aberdeen.Academic Urology UnitItem Systematic review of the clinical effectiveness and cost-effectiveness of rapid point-of-care tests for the detection of genital chlamydia infection in women and men.(2010-06) Hislop, J; Quayyum, Z; Flett, G; Boachie, C; Fraser, C; Mowatt, G; University of Aberdeen.Other Applied Health SciencesItem Systematic reviews of and integrated report on the quantitative, qualitative and economic evidence base for the management of obesity in men(2014-05) Robertson, C; Archibald, D; Avenell, A; Douglas, F; Hoddinott, P; van Teijlingen, E; Boyers, D; Stewart, F; Boachie, C; Fioratou, E; Wilkins, D; Street, T; Carroll, P; Fowler, C; University of Aberdeen.Other Applied Health Sciences; University of Aberdeen.Institute of Applied Health Sciences; University of Aberdeen.Rowett Institute; University of Aberdeen.Health Economics Research UnitItem Types of urethral catheter for reducing symptomatic urinary tract infections in hospitalised adults requiring short-term catheterisation : multicentre randomised controlled trial and economic evaluation of antimicrobial- and antiseptic-impregnated urethral catheters (the CATHETER trial)(2012-11) Pickard, R; Lam, T; Maclennan, G; Starr, K; Kilonzo, M; McPherson, G; Gillies, K; McDonald, A; Walton, K; Buckley, B; Glazener, C M A; Boachie, C; Burr, J; Norrie, J; Vale, L; Grant, A M; N'dow, J; University of Aberdeen.Other Applied Health Sciences; University of Aberdeen.Aberdeen Centre for Evaluation; University of Aberdeen.Health Economics Research Unit; University of Aberdeen.Academic Urology Unit; University of Aberdeen.Institute of Applied Health Sciences